A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of IK-1001 to Evaluate Safety, Pharmacokinetics and Proof-of-Concept Efficacy for Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft(CABG) Surgery

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of IK-1001 to Evaluate Safety, Pharmacokinetics and Proof-of-Concept Efficacy for Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft(CABG) Surgery

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2016

At a glance

  • Drugs Sodium sulfide (Primary)
  • Indications Myocardial reperfusion injury
  • Focus Pharmacodynamics; Pharmacokinetics; Proof of concept
  • Sponsors Ikaria Holdings
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jul 2012 Primary endpoint identified as Area-under-the-drug-concentration-time-curve as reported by European Clinical Trials Database record.
    • 01 Oct 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top